Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Benitec Biopharma's share price for the quarter that ended in Mar. 2024 was $5.25. Benitec Biopharma's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 2.72 Mil. Therefore, Benitec Biopharma's market cap for the quarter that ended in Mar. 2024 was $14.31 Mil.
Benitec Biopharma's quarterly market cap
increased
from Sep. 2023 ($7.70 Mil) to Dec. 2023 ($8.37 Mil) and
increased
from Dec. 2023 ($8.37 Mil) to Mar. 2024 ($14.31 Mil).
Benitec Biopharma's annual market cap
declined
from Jun. 2021 ($34.73 Mil) to Jun. 2022 ($9.48 Mil) and
declined
from Jun. 2022 ($9.48 Mil) to Jun. 2023 ($6.67 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Benitec Biopharma's Enterprise Value for Today is $75.11 Mil.
Benitec Biopharma Market Cap Historical Data
The historical data trend for Benitec Biopharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Benitec Biopharma's Market Cap
For the Biotechnology subindustry, Benitec Biopharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Benitec Biopharma's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Benitec Biopharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Benitec Biopharma's Market Cap falls into.
Benitec Biopharma Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Benitec Biopharma's Market Cap for the fiscal year that ended in Jun. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Benitec Biopharma (NAS:BNTC) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Benitec Biopharma Market Cap Related Terms
Thank you for viewing the detailed overview of Benitec Biopharma's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Benitec Biopharma (Benitec Biopharma) Business Description
Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BNTC has been successfully added to your 